[Treatment of hypertension with obsilazin].
Obsilazin was established to have a good to moderate hypotensive effect in 75% of the treated 36 patients with moderate and severe hypertension under the condition of a 6-month open clinical experiment, not changing the heart rate. The adverse effects are often 69.4%), usually transitory but in 11.1% they proved to be the cause for discontinuation of the treatment.
Sirakova
V
V
Penkov
N
N
Kaponov
Kh
Kh
Dimitrov
G
G
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004078:Dihydralazine / Q000009:adverse effects / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006830:Hydralazine / Q000031:analogs & derivatives*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D004232:Diuretics; D004338:Drug Combinations; C039687:obsilazin; D006830:Hydralazine; D011433:Propranolol; D004078:Dihydralazine
Lechenie na khipertonichnata bolest s obsilazin.